About Us

Our Story

There is always a first.

Every major technological advancement began with the pioneers who dared to step forward, persisted in the face of challenges, and demonstrated indomitable resolve.

In 2008 Moximed recognized an opportunity that others missed. Many before described the important role of load management as a tool against knee OA, yet finally Moximed had the clear vision to design an implantable shock absorber and, through dogged persistence and resolute support from surgeons, refined and demonstrated its distinct clinical value.

A new chapter begins.

The value of a new medical product is proven through positive patient outcomes, and in 2014 Moximed introduced a platform of ISAs designed with a polymer shock absorber. The MISHA Knee System and surgical technique incorporate the knowledge and insight that can only be gained with experience and represent the highest technology that Moximed has ever developed.

The pivotal study data and patient experience validated our efforts, and we look forward to including you on the journey ahead.

Start a career with us

JOIN OUR TEAM

Who We Are

We are trailblazers. Everyday we work to create a new beginning for patients suffering from osteoarthritis.

Anton Clifford, Ph.D

Founder & CEO

Anton had the vision to identify the clinical need and invent the solution of the implantable shock absorber. His confidence to co-found Moximed after a successful rise through small company acquisition (MedNova) and parent company (Abbott) integration, combined with his resilience and sound judgment, serve as guideposts to a growing and ascending Moximed.

Debra Snowdale

CFO

Debra has shepherded commercial-stage medical device companies through high growth periods and M&A processes for over two decades as an accountant (Ernst & Young LLP), founder (ExclusiveCFO Inc), and executive (Philips Medical Systems). Along with these corporate accomplishments, Debra’s involvement in professional organizations, such as the CFO Leadership Council of Silicon Valley and the International Association of Women, allow her to provide a broad strategic perspective to Moximed.

Christine Barcelos

VP Corporate Operations

Christine’s unique ability to lead multiple, diverse functions, helped drive the success of high growth medical technology companies (Kyphon, St. Francis Medical). Her passion for recognizing and recruiting talented team members who contribute to a thriving and entrepreneurial culture is instrumental to Moximed’s growth.

Keith Fong

VP Marketing and Business Development

Keith’s delivered consistent results for medical device stalwarts (Boston Scientific, Guidant) across multiple clinical specialties and functional roles. His nuanced understanding of Moximed’s product and market positioning, combined with an ability to develop and implement highly effective strategies and build enduring customer relationships are essential to Moximed’s success.

Nancy Isaac

Regulatory Counsel & VP Quality Affairs

Nancy’s track record for attaining regulatory product approvals and navigating complicated regulatory pathways is second to none. Her success is based on her professionalism and original, strategic thinking to overcome difficult challenges. While she established her credibility in the Fortune 500 (Becton Dickinson), Nancy thrives as a leader in the world of emerging companies with innovative technologies (NeoTract, Broncus, Avails) and is a pillar of Moximed’s success.

Wendy Sawyer

SVP Operations and Product Development

Wendy is a proven operations leader with a talent for building and scaling manufacturing for breakthrough medical devices. She brings a strategic approach and determined attitude to Moximed after previously heading operations for startups as well as blue-chip medical device companies (NeoTract, Boston Scientific, Guidant).

Rose Weinstein

VP Clinical Affairs

Rose is a clinical research leader, bringing over 15 years of clinical expertise in Class II and III devices, while working for startups and Fortune 500 companies (J&J). Rose gravitates toward novel technologies, especially those that prioritize quality of life. Her leadership and drive to generate high-quality clinical evidence resulted in numerous regulatory approvals, publications, and favorable payer policies while at NeoTract (acquired by Teleflex) and more recently FDA market authorization of the MISHA Knee System while at Moximed.